Navigation Links
FDA Approves BENLYSTA® for Lupus in Breakthrough for Millions of Sufferers
Date:3/9/2011

NEW YORK, March 9, 2011 /PRNewswire-USNewswire/ -- The Lupus Research Institute (LRI) and its National Coalition of state and local lupus organizations welcome the U.S. Food and Drug Administration's (FDA) historic approval of BENLYSTA® (belimumab) for systemic lupus erythematosus (lupus), launching the first safe and effective treatment for lupus in more than half a century.

"This is a moment of enormous relief for people with lupus, and a landmark achievement for the nation's scientists, doctors and industry investigators searching for new answers to lupus," said Margaret G. Dowd, president of the Lupus Research Institute, an organization uniquely dedicated to pioneering discovery through novel research in lupus. "BENLYSTA's winding path to FDA approval is a triumph for the dedicated pursuit of innovative science and smart trial design in achieving solid results in the complex autoimmune disease of lupus."

The FDA announced today that BENLYSTA, developed by Human Genome Sciences (HGS) and GlaxoSmithKline (GSK), is approved for treatment of people with active systemic lupus. This decision followed its Arthritis Advisory Committee's 13-2 vote on November 16, 2010 to recommend the drug's approval.  

The development of BENLYSTA stems from the scientific discovery of a new immune system molecule, BLyS, which revealed a critical new pathway that can be manipulated to treat lupus.  BENLYSTA is founded on novel, fundamental science from industry and academia that explores a range of disease pathways and mechanisms, much like the studies that the LRI has been supporting for a decade.

"With BENLYSTA, physicians can now prescribe an effective new agent to manage the signs and symptoms of lupus, and improve the quality of life of their patients," said David S. Pisetsky, M.D., Ph.D., Professor of Medicine and Immunology at Duke University Medical Center and a member of the LRI Scientific Advisory Board.  

"F
'/>"/>

SOURCE Lupus Research Institute
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 InfinityQS International, ... Manufacturing Intelligence , today announces Infusion Chicago, ... event will be held Oct. 9-10, 2014, at ... designed to showcase the necessity for implementing a ... and Manufacturing Intelligence to gain insight into production ...
(Date:8/21/2014)... 2014  AliveCor, Inc. announced today that ... has granted the company clearance for its ... most common form of cardiac arrhythmia. AliveCor,s ... patients are experiencing AFib through real-time electrocardiogram ... based AliveCor® Heart Monitor, so physicians can ...
(Date:8/21/2014)... N.Y. , Aug. 21, 2014  The board ... ), a leading provider of clinical trial imaging solutions, ... been named chief financial officer, effective immediately.  Mr. Groff ... since August 2013.  He joined VirtualScopics in January 2006 ... in February 2013. "When the board of ...
Breaking Medicine Technology:InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2AliveCor Receives First FDA Clearance to Detect a Serious Heart Condition in an ECG on a Mobile Device 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4
... Inc.,(Amex: CUR ) today announced that it ... Clinic pertaining to Targeted Spinal Cord,Therapeutics Delivery. All ... formerly of Cleveland Clinic, now at Emory University., ... are very pleased to have licensed-in these important ...
... today,announced the Company,s lead product, amadacycline, formerly PTK 0796, ... Breaker,poster presentation at the 48th Interscience Conference on Antimicrobial,Agents ... D.C.,from October 25 - October 28, 2008., More ... Sunday, October 26, 12:15 - 1:15 pm EST ...
Cached Medicine Technology:Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology 2Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology 3Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2
(Date:8/22/2014)... For the first time an oncogenic somatic mutation ... transfection) protein has been identified in small cell lung ... within SCLC cell lines produced increased intracellular signaling and ... of lung cancer representing 15% of all lung cancers ... 85% of lung cancer, has been extensively examined for ...
(Date:8/22/2014)... 2014 Paying tuition and other related ... coming year for four nurse educators pursuing advanced degrees, ... for Nursing Foundation for Nursing Education . This year’s ... $10,000 more than in 2013, thanks to these named ... Elizabeth Isaac Marcil Endowment Funds, both donated by Kathy ...
(Date:8/22/2014)... New York, New York (PRWEB) August 22, 2014 ... ) continue to be filed in U.S. courts ... cardiovascular events due to their use of prescription ... to court documents, a new claim was filed ... California man who allegedly suffered life-threatening heart issues ...
(Date:8/22/2014)... 2014 CarePoint Health is proud ... Medicine, Geriatrics, Hospice and Palliative Care, Dr. Michelle ... Group. Their system welcomes Dr. Reisner to the ... comprise CarePoint Health Medical Group, a comprehensive network ... representing a wide range of specialties. This latest ...
(Date:8/22/2014)... FRIDAY, Aug. 22, 2014 (HealthDay News) -- Back-to-school time ... plan that fits into the family schedules, an expert ... a child,s school year can also be the start ... Karin Richards, a professor of kinesiology at the University ... news release. With kids, extracurricular activities likely to ...
Breaking Medicine News(10 mins):Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:With Kids in School, Parents Can Work Out 2
... new study shows anemia may double the risk of ... erode the ability to live independently. Researchers say seniors ... are just above the traditional cut-off point for the ... declines than those who have normal blood hemoglobin levels.// ...
... than 2 million people worldwide and is caused by abnormal ... in seizures. More than half of those with epilepsy can ... is under way to determine just how effective surgery is ... epilepsy, //the most common form of the disorder.,Typically, about 80 ...
... today, be careful how much fluid you drink. Too much ... fatal outcome. ,The warning follows reports of several deaths from ... excessive drinking known as hyponatremic encephalopathy. Since the cause of ... Science Institute of South Africa, says it is preventable.,// ...
... low in saturated fats can lower bad cholesterol as effectively ... medication-free cholesterol control may be viable for some people. Researchers ... in okra, eggplant, soy proteins, oatmeal //and almonds resulted in ... just one month. ,Participants on a low-fat diet ...
... through activities such as reading, doing puzzles or playing ... cognitive abilities as you age. ,That's the message from ... of the New England Journal of Medicine. ,Researchers from ... found seniors who participated in mind-stimulating leisure activities had ...
... - When HIV-infected patients alternated their drug regimen ... longer than when one regimen was administered continuously. ... Therapy Combination against HIV-1) study. Dr. Javier Martinez-Picado, ... Spain, and others examined this alternating strategy among ...
Cached Medicine News:
... Graham-Field has been developing ... than 58 years. Our medical-surgical ... reputation for innovation, quality and ... brands include the Labtron® line ...
... Air Entrainment Nebulizers deliver particulate humidity in ... your chronic secretion patients. For your convenience, ... existing supply of sterile water., ,The ... FiO2's of 20-50% with a total flow ...
... metered dose inhalers., ,ACE ensures prompt, ... canisters. Its versatile design allows it to ... conjunction with an endotracheal airway or resuscitation ... may also be used in conjunction with ...
... Airial Handheld Ultrasonic Nebulizer has ... This compact, portable, and lightweight ... fast & quite treatments operating ... or DC auto adapter. , ...
Medicine Products: